A modern psychedelic revolution is underway. After the floodgates opened for marijuana legalization, especially after the stigma associated with medical marijuana, there has been a renewed interest in cannabinoids as medicines.

The number of people has increased in the past two years psychedelic company Committed to changing the face of healthcare, there are more trials than ever conducted with psilocybin to DMT to treat a wide range of diseases and disorders.

in November wonderland The Psychedelic Business Conference, where many of the best and brightest in the industry come together in Miami to share their progress, learn from each other, and showcase the latest developments in this rapidly emerging field.

Hosted by Microdose, the inaugural annual event attracted nearly 2,000 entrepreneurs, thought leaders and investors for two days of interactive panel discussions, engaging events and networking opportunities.

The multi-faceted agenda at the Adrienne Arsht Performing Arts Centre covers a wide range of topics.

Speakers touched on psychedelic therapies ranging from addiction to PTSD, the state of investors, cutting-edge scientific discoveries and the state of political reform.

A workshop discussing the ways entheogens could improve sex brought a crowd who could only stand in the room to the green room of the venue, while the overflow crowd poured into the lobby.

Boxer Mike Tyson and former NHL player Daniel Casillo take to the packed audience to talk about their personal success with psychedelics as a way to deal with the physical and mental suffering they suffer in professional and personal lives trauma.

Tyson, who admits to ingesting the venom of a Bufo alvarius toad 60 times over the past few years, believes entheogens have made him a better person, but insists his presence in space is greater than his. The discovery went viral after the former world champion told the crowd he “died” during his first toad experience.

“I’m proud to be here today to share my thoughts on the drugs that made me who I am, but it’s all about the universe — it’s not about me,” Tyson said. Cannabis and Technology Today.

When asked how people support the psychedelic field, Tyson said:

“Don’t take my word for it – do it,” encourages everyone to try entheogens for themselves.

Frontier R&D Display

The rapid development of scientific discoveries in the psychedelic field was a hot topic at the Wonderland conference, with several public companies and organizations presenting their latest developments.

During an early morning press conference, members of Cybin’s leadership team provided an update on the creation of a novel psilocybin analog. The drug, currently called CYB003, is designed to mimic the magic mushroom experience but with a shorter onset and duration, which the company believes will make the drug more accessible.

The company plans to enter the clinical trial phase of CYB003 in 2022.

“Actually, I was surprised by the progress,” Sabine CEO Doug Drysdale told Cannabis and Technology Today“It can typically take three years from discovery of a molecule to submission of an IND application to the FDA. We’ll be there in about 15 months, which is fantastic.”

Dr. Joe Tucker, Chief Executive Officer Envi Biosciences, speaking on the “Next Level Psychedelics” panel, shared the many ways his company is looking to expand the potential of entheogen-based therapies.

“We’ve actually started looking for non-psychedelic molecules that have the same powerful ability to rewire the brain, but without the visual and auditory hallucinations.”

Rick Doblin, Founder Multidisciplinary Association for Psychedelic Studies (MAPS), in a conversation with Microdose founder Patrick Moher, shares his insights on the state of the industry with CEO Amy Emerson.

When asked about the intersection of sacred medicine and pharmaceutical capitalism, Doblin insists that as long as people are recovering, there is room for all interpretations.

“You can do clinical therapy at the same time as religious therapy. I think there will be a similarity,” said Dobrin, citing a Brazilian study in which ayahuasca was used in a hospital setting for patients with depression, and with remarkable success.

“Medical has insurance, religion doesn’t,” Doblin noted.

Microdosing Awards highlight the best and brightest

One of the highlights of the Wonderland event was the announcement of the winners of the first annual Microdosing Awards.

The award recognizes outstanding achievement by individuals and organizations from all categories in the psychedelic field.

Winners include Paul Stamets (Public Person of the Year), Robin Carhart-Harris (Scholar of the Year), Gwella’s Mojo Microdose (Consumer Product of the Year) and Cybin (Company of the Year).

Author Michael Pollan’s work on psychedelic botanical medicine has received international acclaim, receiving two honors: Writer of the Year and an Industry Pioneer Lifetime Achievement Award.

“The public has recognized and appreciated that Michael’s first-person exploration of psychedelics taught him not only about the mind, but also about the mind, especially about the nature of spiritual experience,” Moher said.

Microdosing plans more live events, online programming continues

The success of the inaugural Wonderland conference has organizers already looking ahead to plan the next iteration. Doblin initially shied away from the idea of ??attending a psychedelic business conference, but was stunned by the turnout.

“I was surprised how many people came [to Wonderland] come from all around the world! “He said. “It’s an incredible opportunity. “

For those looking to engage with Microdose before the next conference is announced, the platform’s popular monthly Psychedelic Capital series is a great way to learn about the thriving space virtually. Archived shows are also available online.